NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA ("HBC" or the "Company") earlier today regarding the launch of a private placement ...

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a me ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If you currently own BioXcel stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. ...

Key Takeaways Regeneron to post Q3 results on Oct. 28, with earnings forecast at $9.54 per share on $3.60B revenues.Dupixent profits likely rose on 26.2% higher sales across multiple approved disease indications.Strong demand for Eylea HD could offset declines in Eylea. Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports third-quarter 2025 results on Oct. 28, 2025.The Zacks Consensus Estimate for revenues is pegged ...

Shares of Ocular Therapeutix (OCUL) have been struggling lately and have lost 6.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot- Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. SINOVAC Announces Appointment of Independent Auditor Share Critical step in improving transparency and resuming ...

Core Viewpoint - Eli Lilly announced its acquisition of Adverum Biotechnologies, a gene therapy developer, in a deal valued at up to $261.7 million, aimed at enhancing its pipeline for experimental treatments for eye diseases [1] Company Summary - The acquisition is part of Eli Lilly's strategy to strengthen its product offerings in the gene therapy space, particularly focusing on eye diseases [1] - The deal reflects Eli Lilly's commitment to expanding its research and development capabilities in innovative therapies [1] Industry Summary - The gene therapy market is experiencing significant growth, with increasing interest from major pharmaceutical companies looking to invest in innovative treatment options [1] - This acquisition highlights the competitive landscape in the biotechnology sector, where companies are actively seeking to enhance their portfolios through strategic mergers and acquisitions [1]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by 1% on Friday [1] - The Dow Jones rose by 0.80% to 47,108.01, while the S&P 500 gained 0.83% to 6,794.12 [1] - Information technology shares saw a notable increase of 1.3%, while materials stocks declined by 0.3% [1] Company Performance - Procter & Gamble Co. reported better-than-expected earnings per share (EPS) of $1.99 for Q3, a 3% increase year-over-year, surpassing the analyst consensus of $1.90 [2] - The company's quarterly sales reached $22.386 billion, exceeding the expected $22.175 billion [2] - Procter & Gamble raised its fiscal 2026 adjusted EPS guidance to a range of $6.83-$7.10, compared to the previous range of $6.83-$7.09 and above the analyst estimate of $6.97 [3] - The sales outlook for fiscal 2026 was adjusted to $85.127 billion-$88.498 billion, slightly up from the previous range and below the expected $86.919 billion [3] Stock Movements - Wellgistics Health, Inc. shares surged by 183% to $1.17 following a non-binding letter of intent with Datavault AI Inc. [8] - Genenta Science S.p.A. saw its shares increase by 145% to $7.93 due to an expanded collaboration with ANEMOCYTE [8] - Neuphoria Therapeutics Inc. shares rose by 89% to $7.61 after a significant share purchase by a shareholder [8] - Conversely, Picard Medical, Inc. shares dropped by 72% to $3.67, and MultiSensor AI Holdings, Inc. shares fell by 46% to $0.7304 after announcing a private placement [8] Economic Indicators - The S&P Global services PMI increased to 55.2 in October from 54.2 in September, surpassing market expectations of 53.5 [11] - The S&P Global manufacturing PMI rose to 52.2 in October from 52.0, exceeding estimates of 52.0 [11] - The S&P Global composite PMI jumped to 54.8 in October from 53.9 in September [11]

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a July 29, 2 ...

Lilly said it reached a deal to buy Adverum Biotechnologies, a company working to treat blindness, as it continues a push into gene therapies https://t.co/HP0w3WElUW ...